Name | Title | Contact Details |
---|---|---|
Joan Connolly |
Chief Technology Officer | Profile |
Tyson Kamikawa |
Vice President Information Technology | Profile |
ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.
Bionical Emas is the first and only CRO that combines Clinical Development, Early Access Programs and Clinical Trial Supply. We build close partnerships with our clients, so we can provide you with a unique, integrated service shaped to fit your needs.
Founded in 2007, we are a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases. Our vision is to empower humanity with a healthier future through transformative science. Our mission is to leverage the Trimer-Tag™ technology platform and manufacturing capabilities for the discovery, development and commercialization of novel vaccines and biologic therapies.
Caravel Autism Health provides early intervention to treat signs & symptoms of Autism. We serve families in Green Bay, Milwaukee, Madison, Wausau & Chicago.
Sudmo North America is a Machesney Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.